Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customers
5. Egypt Pharmaceutical Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Type (Pharmaceutical Drugs v/s Biologics)
5.2.1.1. By Pharmaceutical Drugs (Gynaecology Drugs, Respiratory Drugs, Dermatology Drugs, Analgesic Drugs, Oncology Drugs, Others)
5.2.1.2. By Biologics (Monoclonal Antibodies (MAbS, Therapeutic Proteins, Vaccines)
5.2.2. By Drug Classification (Branded Drugs v/s Generic Drugs)
5.2.3. By Mode of Purchase (Prescription-Based Drugs v/s Over-the-counter Drugs)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
6. Egypt Branded Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.1.1. By Pharmaceutical Drugs
6.2.1.2. By Biologics
6.2.2. By Mode of Purchase
6.2.3. By Distribution Channel
7. Egypt Generic Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.1.1. By Pharmaceutical Drugs
7.2.1.2. By Biologics
7.2.2. By Mode of Purchase
7.2.3. By Distribution Channel
8. Market Dynamics
8.1. Drivers
8.2. Challenges
9. Market Trends & Developments
10. Policy & Regulatory Landscape
11. Egypt Economic Profile
12. Competitive Landscape
12.1. Amoun Pharmaceutical Company
12.2. EIPICO
12.3. Memphis Pharmaceutical and Chemical Industries
12.4. MDI Pharma
12.5. Merck & Co.
12.6. Novartis AG
12.7. Pharco Pharmaceuticals
12.8. Roche Holding AG
12.9. Sanofi S.A
12.10. EVA Pharma
12.11. Orchidia Pharmaceutical Industries
12.12. GlaxoSmithKline
12.13. Tabuk Pharmaceuticals
13. Strategic Recommendations